TIRmed Pharma Publishes New Mechanistic Findings on TIR-01 in European Journal of Immunology

TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, announces the publication of new research on its immunomodulatory oligonucleotide TIR-01 in the European Journal of Immunology. The study provides mechanistic insight into how TIR-01 affects human monocyte differentiation and supports the development of tolerogenic dendritic cells—processes that are central to immune regulation in inflammatory skin diseases such as atopic dermatitis (eczema).[TIRmed-Pharma-publishes-new-mechanistic-findings-TIR-01-EJI.png] The work builds on earlier